MEDS · DataMEDS AI, Inc.

This amendment clarifies that the Amended Settlement Agreement executed on February 9, 2026 is the material definitive agreement triggering Item 1.01 disclosure — a procedural correction rather than a substantive change to the underlying arrangement. The amendment does not disclose new terms, financial impact, or conditions beyond confirming the agreement’s existence and effective date. Because the Original Settlement Agreement was already reported, and no new obligations, payments, or strategic implications are revealed, the amendment primarily addresses SEC compliance and disclosure accuracy. Investors should note that the absence of additional detail — such as settlement amounts, release scope, or operational consequences — limits immediate financial or governance implications. However, the fact that a formal amendment was required may indicate evolving negotiation dynamics or legal refinements between the parties, warranting attention in future disclosures if related matters resurface.